Experience of using rezorby in treating patients with prostate cancer with metastases in the bones of the skeleton

Rezorba is quite effective and safe drug from the group of bisphosphonates. Treatment Rezorba convenient for patients, as administered in the form of short-term infusion of 1every 3-4 weeks and can be performed on an outpatient basis. In the obtained data at this stage, it is shown that fast Rezorba suppresses pain syndrome, provide effective protection of bone tissue, inhibits the degradation of the skeletal bones and promotesbone regeneration, improving quality of life in patients with metastatichormone-refractory prostate cancer. Also, the drug was well tolerated in combinationwith anticancer therapy, and not inferior to foreign analogues in quality. Thus, the drug Rezorba can occupy an important place in the combined therapy of prostate cancer patients with bone metastases.